1581-P: Evaluation of a Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service

Introduction & Objective: The purpose of this study is to evaluate the impact of pharmacist integration into the management of patients with MASLD. There are no known studies to date that have investigated the impact of a pharmacist integration within a hepatology clinic for MASLD management. The primary objectives are pharmacist intervention types and 6 month and 12 month clinical outcomes.

Methods: This is a retrospective cohort study of 220 patients referred to the clinical pharmacy service and/or a group patient education program coordinated by the pharmacist, between July 2018 to December 2021. Inclusion criteria included adult patients with established care at a Hepatology clinic with a formal diagnosis of MASLD by liver biopsy or non-invasive testing who have at least one cardiometabolic risk factor. Information on patient demographics, pharmacist interventions, and baseline, 6 month, and 12 month post-intervention clinical parameters were collected from the Electronic Medical Record. Data was analyzed using descriptive statistics, Paired t test, and Wilcoxon Signed Rank Test.

Results: Majority of patients were living with obesity (74.1%) and had Alanine Transaminase (ALT) elevations at baseline (60%). The most frequent pharmacist intervention was cardiometabolic medication recommendations. Weight loss from baseline was demonstrated at 6 months (5.09 lbs, p<0.05) and maintained at 12 months (6.9 lbs, p<0.05). Reduction in ALT was also observed at 6 months (14.38 U/L, p<0.05) and 12 months (20.15 U/L, p<0.05). Reductions were seen in Hemoglobin A1c (0.26%, p<0.05), Low-Density Lipoprotein (9.23mg/dL, p<0.05), and Triglycerides (16.63mg/dL, p=0.0629) at 12 months.

Conclusion: Patients referred to this novel clinical pharmacy service demonstrated significant and sustained weight and ALT reduction at 12 months, which may translate into MASLD improvement. They also experienced significant improvements in most cardiovascular clinical parameters.